DISC MEDICINE INC

Disc Medicine, Inc. is a clinical-stage biotechnology company whose lead drug candidate, bitopertin, is a small molecule designed to treat erythropoietic protoporphyria (EPP). The development of such pharmaceuticals requires preclinical testing on animals as a standard regulatory step to assess safety and efficacy before human trials. This business model is inherently reliant on the commercial exploitation of animals for research and development.

The company's primary asset, bitopertin, recently received a Complete Response Letter from the FDA in February 2026, indicating the regulatory pathway forward requires further data before approval. This development underscores that the company's core value proposition remains tied to a product pipeline dependent on animal testing. As a clinical-stage entity with no marketed products, Disc Medicine's operations and investor valuation are singularly focused on advancing drug candidates through preclinical and clinical stages, a process that systematically utilizes animals.